Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Preclinical study has shown that human colorectal cancer cells harboring KRAS or BRAF
mutations are selectively killed by high levels of ascorbic acid (AA). High dose of AA aslo
impairs tumor growth in Apc/KRASG12D mutant mice. Previous phase Ⅰ studies have found that
high dose iv AA is well tolerated in cancer patients.This protocol is a phase Ⅲ study of AA
infusions combined with treatment with FOLFOX +/- bevacizumab versus treatment with FOLFOX
+/- bevacizumab alone as first-line therapy in patients with recurrent or advanced colorectal
cancer.